Small Animal Imaging Facility Shared Resource

项目摘要/摘要 在威斯康星大学碳骨癌中心(UWCCC)下运作的小动物成像 设施(SAIF)为以下UWCCC成员提供创新、经济高效的高分辨率成像支持 在他们的研究中使用小动物模型。学院领导和设施经理提供指导 研究人员确保成像方式和实验设计最适合他们的癌症 问题。结合正电子发射/计算机断层扫描(PET/CT)、磁共振成像(MRI)、 超声(US)、光声学和/或光学生物发光/荧光/近红外(NIR)成像 对于所有主要的小动物成像模式，SAIF提供了访问途径。此外，UWCCC 调查人员可以选择他们想要的服务交付级别，范围从图像采集、重建、 和分析的解释，和/或演示幻灯片的准备。必要时，商业或专有 显像剂是为研究人员购买的，并在使用前确保其质量。赛义夫撑着伞 动物使用、生物安全和辐射安全协议，从而确保对成像的适当监管控制 在进行研究的同时，最大限度地减少对个人调查人员的监管负担。毗邻同类地区 临床研究扫描仪，SAIF致力于设计新显像剂的临床前成像评估 考虑到最终的临床翻译。其中一种名为CLR1404的药物经过了广泛的临床前评估 在转化为8项临床影像和放射治疗试验之前，在SAIF内进行。在当前CCSG资助期间 在此期间，SAIF已向65个独特的UWCCC成员提供关键的成像支持，这些成员代表所有六个成员 UWCCC计划。我们继续评估新的成像和相关技术，如果合适和相关的话 对于成员，制定一项计划，将这些新技术引入该设施。我们的具体目标是：1) 为UWCCC成员提供对最先进的小动物癌症成像的无缝访问和指导 用于新疗法的基本临床前评估的技术；以及2)提供临床前发现和 对新的分子成像和治疗药物的开发支持。CCSG提供的资金是 在支持我们的使命方面至关重要，即在尽可能高的水平上为UWCCC成员服务，同时将 在相对昂贵的以技术为中心的领域中的成本。我们期望我们在发展和评估中发挥的作用 新的成像和治疗药物，特别是那些由我们自己的成员开发的药物，以及 通过成像对新的治疗剂进行评估，最终将允许个性化的治疗计划和 改善癌症患者的生活质量和生存结果。

PROJECT SUMMARY/ABSTRACT Operating under the University of Wisconsin Carbone Cancer Center (UWCCC), the Small Animal Imaging Facility (SAIF) provides innovative, cost effective, high-resolution imaging support to UWCCC members who utilize small animal models in their research. The Faculty Leader and Facility Manager provide guidance to investigators ensuring the imaging modality and experimental design are best suited to address their cancer question. Incorporating positron emission/computed tomography (PET/CT), magnetic resonance imaging (MRI), ultrasound (US), photoacoustics, and/or optical bioluminescence/fluorescence/near-infrared (NIR) imaging modalities, the SAIF affords access to all major small animal imaging modalities. Moreover, UWCCC investigators can select their desired level of service deliverables ranging from image acquisition, reconstruction, and interpretation to analysis, and/or presentation slide preparation. When necessary, commercial or proprietary imaging agents are acquired for investigators and their quality ensured prior to use. The SAIF holds umbrella animal use, biosafety, and radiation safety protocols thus assuring appropriate regulatory control of imaging studies while minimizing the regulatory burden placed on individual investigators. Located adjacent to similar clinical research scanners, the SAIF strives to design preclinical imaging assessment of new imaging agents with eventual clinical translation in mind. One such agent, CLR1404, underwent extensive preclinical evaluation within the SAIF prior to translating into 8 clinical imaging and radiotherapy trials. During the current CCSG funding cycle, the SAIF has provided critical imaging support to 65 unique UWCCC members representing all six UWCCC programs. We continue to assess new imaging and related technologies and, if suitable and relevant to the membership, develop a plan to bring such new technologies into the facility. Our specific aims are to; 1) provide UWCCC members seamless access and guidance to the most advanced small animal cancer imaging technologies for essential preclinical assessment of new therapies; and 2) to provide preclinical discovery and development support for new molecular imaging and diapeutic agents. Funding provided from the CCSG is critical in supporting our mission to serve the UWCCC membership at the highest level possible while minimizing costs in a relatively expensive technology-centric field. We expect that our role in the development and evaluation of new imaging and therapy agents, especially those being developed by our own membership, as well as the assessment of new therapeutic agents via imaging, will ultimately permit personalized treatment planning and improve the quality of life and survival outcomes of cancer patients.